Content
07/29/2025
Cambridge, MA USA
ARTBIO
completed $132 million Series B Round funding. Investors include
B Capital (lead), Sofinnova Investments (lead), F-Prime Capital, Omega Funds, Third Rock Ventures, Qatar Investment Authority, Alexandria Venture Investments.
About
ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.
Startup
Sector:
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
